Blood collection tubes as medical devices: The potential to affect assays and proposed verification and validation processes for the clinical laboratory

被引:29
作者
Bowen, Raffick A. R. [1 ]
Adcock, Dorothy M. [2 ]
机构
[1] Stanford Univ, Med Ctr, Dept Pathol, Rm H1401J,300 Pasteur Dr, Stanford, CA 94305 USA
[2] Lab Corp Amer Holdings, Colorado Coagulat, Englewood, CO USA
关键词
Blood; Collection; Preanalytical; Tube; Validation; Verification; MAGNESIUM CONTAMINATION; SODIUM-FLUORIDE; UNITED-STATES; SERUM; INTERFERENCE; QUALITY; TESTOSTERONE; STABILITY; ANALYTES; LIPEMIA;
D O I
10.1016/j.clinbiochem.2016.10.004
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Blood collection tubes (BCTs) are an often under-recognized variable in the preanalytical phase of clinical laboratory testing. Unfortunately, even the best-designed and manufactured BCTs may not work well in all clinical settings. Clinical laboratories, in collaboration with healthcare providers, should carefully evaluate BCTs prior to putting them into clinical use to determine their limitations and ensure that patients are not placed at risk because of inaccuracies due to poor tube performance. Selection of the best BCTs can be achieved through comparing advertising materials, reviewing the literature, observing the device at a scientific meeting, receiving a demonstration, evaluating the device under simulated conditions, or testing the device with patient samples. Although many publications have discussed method validations, few detail how to perform experiments for tube verification and validation. This article highlights the most common and impactful variables related to BCTs and discusses the validation studies that a typical clinical laboratory should perform when selecting BC's. We also present a brief review of how in vitro diagnostic devices, particularly BCTs, are regulated in the United States, the European Union, and Canada. The verification and validation of BCTs will help to avoid the economic and human costs associated with incorrect test results, including poor patient care, unnecessary testing, and delays in test results. We urge laboratorians, tube manufacturers, diagnostic companies, and other researchers to take all the necessary steps to protect against the adverse effects of BCT components and their additives on clinical assays. (C) 2016 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:1321 / 1330
页数:10
相关论文
共 74 条
[1]   Effect of interference from hemolysis, icterus and lipemia on routine pediatric clinical chemistry assays [J].
Agarwal, Shweta ;
Vargas, German ;
Nordstrom, Cristina ;
Tam, Estella ;
Buffone, Gregory J. ;
Devaraj, Sridevi .
CLINICA CHIMICA ACTA, 2015, 438 :241-245
[2]  
[Anonymous], METHOD COMP BIAS EST
[3]  
[Anonymous], PROC HANDL PROC BLOO
[4]  
[Anonymous], PROC COLL DIAGN BLOO
[5]  
[Anonymous], LAB MED NAT STAT REP
[6]  
[Anonymous], 14820 EN
[7]  
[Anonymous], BIOCH MED
[8]  
[Anonymous], PREANALYTICAL ERRORS
[9]  
[Anonymous], USER VERIFICATION PE
[10]  
[Anonymous], 2012, ELSEVIER SCI INT C S